Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 157Carcinoma, Intraductal, Noninfiltrating 16Breast Carcinoma In Situ 12Neoplasm Metastasis 9Ovarian Neoplasms 7Breast Neoplasms, Male 7Neoplasms 4Prostatic Neoplasms 3Inflammatory Breast Neoplasms 3Glioblastoma 3Breast Cancer Female 3Urinary Bladder Neoplasms 2Recurrence 2Pancreatic Neoplasms 2Obesity 2Infertility 2Hot Flashes 2Fibroadenoma 2Fallopian Tube Neoplasms 2Endometrial Neoplasms 2ER+ Breast Cancer 2Brain Neoplasms 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Sleep Wake Disorders 1Sexuality 1Risk Reduction Behavior 1Rhabdoid Tumor 1Pyloric Stenosis, Hypertrophic 1Primary Breast Cancer 1

Interventions

Docetaxel 4Epirubicin 3Cyclophosphamide 3Paclitaxel 2Vinorelbine 1Tamoxifen 1Iodine-123 1Fluorouracil 1Doxorubicin 1Carboplatin 1CP protocol 1Anthracyclines 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Primary Breast Cancer × Tamoxifen × Clear all
NCT00793377 2008-11-19

Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Docetaxel (AC-Doc) Versus Dose-Dense Doxorubicin and Docetaxel (ADoc) in Breast Cancer

GBG Forschungs GmbH

Phase 3 Completed
913 enrolled
Breast

Primary Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡